1
Phillip Dan Cook, Andrew Mamoro Kawasaki: Sugar modified oligonucleotides that detect and modulate gene expression. ISIS Pharmaceuticals, Woodcock Washburn Kurtz Mackiewicz & Norris, September 23, 1997: US05670633 (346 worldwide citation)

Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected seq ...


2
Phillip Dan Cook, Muthiah Manoharan, Kanda S Ramasamy: Substituted purines and oligonucleotide cross-linking. ISIS Pharmaceuticals, Woodcock Washburn Kurtz Mackiewicz & Norris, October 28, 1997: US05681941 (259 worldwide citation)

This invention is directed to novel purine-based compounds for inclusion into oligonucleotides. The compounds of the invention, when incorporated into oligonucleotides are especially useful as "antisense" agents--agents that are capable of specific hybridization with a nucleotide sequence of an RNA. ...


3
Kelly Teng, Yogesh S Sanghvi, Phillip Dan Cook: Heteroatomic oligonucleoside linkages. Isis Pharmaceuticals, Woodcock Washburn Kurtz Mackiewicz & Norris, October 14, 1997: US05677437 (257 worldwide citation)

Oligonucleotide-mimicking macromolecules that have improved nuclease resistance are provided. Replacement of the normal phosphorodiester inter-sugar linkages found in natural oligonucleotides with four atom linking groups provide unique compounds that are useful in regulating RNA expression and in t ...


4
Phillip Dan Cook: PNA-DNA-PNA chimeric macromolecules. Isis Pharmaceuticals, Woodcock Washburn Kurtz Mackiewicz & Norris, December 23, 1997: US05700922 (218 worldwide citation)

Macromolecules are provided that have increased nuclease resistance, increasing binding affinity to a complementary strand, and that activate RNase H enzyme. The macromolecules have the structure PNA-DNA-PNA where the DNA portion is composed of subunits of 2'-deoxy-erythro-pentofuranosyl nucleotides ...


5
Andrei P Guzaev, Phillip Dan Cook, Muthiah Manoharan, Balkrishen Bhat: Nucleosidic and non-nucleosidic folate conjugates. ISIS Pharmaceuticals, Woodcock Washburn Kurtz Mackiewicz & Norris, January 1, 2002: US06335434 (165 worldwide citation)

Oligonucleotide-folate conjugates are described wherein folates are conjugated to one or more sites on an oligonucleotide including the 2′-, 3′-, 5′-, nucleobase and internucleotide linkage sites. The folate can be attached via the &agr;- or &ggr;-carboxylate, optionally through a linking group. Met ...


6
Balkrishen Bhat, Neelima Bhat, Anne B Eldrup, Thazha P Prakash, Marija Prhavc, Quanlai Song, Phillip Dan Cook, Steven S Carroll, Malcolm Maccoss, David B Olsen: Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase of hepatitis C virus. Merck & Co, Isis Pharmaceuticals, Philippe L Durette, Melvin Winokur, August 17, 2004: US06777395 (141 worldwide citation)

The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are partic ...


7
Phillip Dan Cook: Oligonucleotides having chiral phosphorus linkages. Isis Pharmaceuticals, Woodcock Washburn Kurtz Mackiewicz & Norris, May 29, 2001: US06239265 (133 worldwide citation)

Sequence-specific oligonucleotides are provided having substantially pure chiral Sp phosphorothioate, chiral Rp phosphorothioate, chiral Sp alkylphosphonate, chiral Rp alkylphosphonate, chiral Sp phosphoamidate, chiral Rp phosphoamidate, chiral Sp phosphotriester, and chiral Rp phosphotriester linka ...


8
Phillip Dan Cook, Glenn Hoke: Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity. Isis Pharmaceuticals, Woodcock Washburn Kurtz Mackiewicz & Norris, August 26, 1997: US05661134 (121 worldwide citation)

Sequence-specific phosphorothioate oligonucleotides comprising nucleoside units which are joined together by either substantially all Sp or substantially all Rp phosphorothioate intersugar linkages are provided. Such sequence-specific phosphorothioate oligonucleotides having substantially chirally p ...


9
Muthiah Manoharan, Andrew M Kawasaki, Phillip Dan Cook, Allister S Fraser, Thazha P Prakash: 2-O-acetamido modified monomers and oligomers. Isis Pharmaceuticals, Woodcock Washburn Kurtz Mackieicz & Norris, November 14, 2000: US06147200 (119 worldwide citation)

Nucleosidic monomers and oligomeric compounds prepared therefrom are provided. Also provided is a novel method of deprotection of oligomeric compounds. Oligomeric compounds having at least one 2'-O-acetamido modified nucleosidic monomer are expected to have increased nuclease resistance and binding ...


10
Phillip Dan Cook, Muthiah Manoharan, Balkrishen Bhat: Oligonucleotide-folate conjugates. Isis Pharmaceuticals, Woodcock Washburn, March 4, 2003: US06528631 (119 worldwide citation)

Oligonucleotide-folate conjugates are described wherein folates are conjugated to one or more sites on an oligonucleotide including the 2′-, 3′-, 5′-, nucleobase and internucleotide linkage sites. The folate can be attached via the &agr;- or &ggr;-carboxylate, optionally through a linking group. Met ...